Clinical value of immunoglobulin A antitransglutaminase assay in the diagnosis of celiac disease

Antonella Diamanti, Franco Colistro, Angelica Calce, Rita Devito, Francesca Ferretti, Antonio Minozzi, Alexandra Santoni, Massimo Castro

Research output: Contribution to journalArticle

Abstract

OBJECTIVES. Our goal was to evaluate the possible correspondence between antitissue transglutaminase of immunoglobulin A class levels and stage of mucosal damage in patients affected by celiac disease. In addition, we assessed clinical use of antitissue transglutaminase values to predict biopsy results. METHODS. One thousand eight hundred eighty-six consecutive patients with symptoms suggestive of celiac disease and 305 healthy controls underwent determination of serum levels of immunoglobulin A and antitissue transglutaminase. An intestinal biopsy was performed in subjects with antitissue transglutaminase levels ≥4 IU/mL and in subjects with negative antitissue transglutaminase levels but with clinical suspicion of celiac disease. Histologic grading of celiac disease was consistent with the Marsh classification. RESULTS. One hundred eighty-six subjects with positive antitissue transglutaminase levels and 91 patients with negative antitissue transglutaminase levels were submitted to biopsy. In all healthy subjects, antitissue transglutaminase results were negative. Histologic evaluations in patients with positive antitissue transglutaminase levels gave the following results: type 0 in 25 patients, type 1 in 3 patients, type 2 in 4 patients, type 3a in 22 patients, type 3b in 74 patients, and type 3c in 58 patients. None of the patients with negative antitissue transglutaminase levels showed histologic findings suggestive of celiac disease. The mean antitissue transglutaminase values in patients without mucosal atrophy were significantly lower than in patients with mucosal atrophy. Antitissue transglutaminase values ≥20 IU/mL were found in only 1 patient without mucosal atrophy. CONCLUSIONS. Our study found a strong correspondence between antitissue transglutaminase levels and stage of mucosal injury; antitissue transglutaminase values >20 IU/mL seemed to be strongly predictive of mucosal atrophy.

Original languageEnglish
JournalPediatrics
Volume118
Issue number6
DOIs
Publication statusPublished - Dec 2006

Fingerprint

Transglutaminases
Celiac Disease
Immunoglobulin A
Atrophy
Biopsy
Wetlands
Immunoglobulin Isotypes
Healthy Volunteers

Keywords

  • Antitissue transglutaminase
  • Celiac disease
  • Marsh classification

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health

Cite this

Clinical value of immunoglobulin A antitransglutaminase assay in the diagnosis of celiac disease. / Diamanti, Antonella; Colistro, Franco; Calce, Angelica; Devito, Rita; Ferretti, Francesca; Minozzi, Antonio; Santoni, Alexandra; Castro, Massimo.

In: Pediatrics, Vol. 118, No. 6, 12.2006.

Research output: Contribution to journalArticle

Diamanti, Antonella ; Colistro, Franco ; Calce, Angelica ; Devito, Rita ; Ferretti, Francesca ; Minozzi, Antonio ; Santoni, Alexandra ; Castro, Massimo. / Clinical value of immunoglobulin A antitransglutaminase assay in the diagnosis of celiac disease. In: Pediatrics. 2006 ; Vol. 118, No. 6.
@article{ea00ee42941c4703b1c61dc1378c30c0,
title = "Clinical value of immunoglobulin A antitransglutaminase assay in the diagnosis of celiac disease",
abstract = "OBJECTIVES. Our goal was to evaluate the possible correspondence between antitissue transglutaminase of immunoglobulin A class levels and stage of mucosal damage in patients affected by celiac disease. In addition, we assessed clinical use of antitissue transglutaminase values to predict biopsy results. METHODS. One thousand eight hundred eighty-six consecutive patients with symptoms suggestive of celiac disease and 305 healthy controls underwent determination of serum levels of immunoglobulin A and antitissue transglutaminase. An intestinal biopsy was performed in subjects with antitissue transglutaminase levels ≥4 IU/mL and in subjects with negative antitissue transglutaminase levels but with clinical suspicion of celiac disease. Histologic grading of celiac disease was consistent with the Marsh classification. RESULTS. One hundred eighty-six subjects with positive antitissue transglutaminase levels and 91 patients with negative antitissue transglutaminase levels were submitted to biopsy. In all healthy subjects, antitissue transglutaminase results were negative. Histologic evaluations in patients with positive antitissue transglutaminase levels gave the following results: type 0 in 25 patients, type 1 in 3 patients, type 2 in 4 patients, type 3a in 22 patients, type 3b in 74 patients, and type 3c in 58 patients. None of the patients with negative antitissue transglutaminase levels showed histologic findings suggestive of celiac disease. The mean antitissue transglutaminase values in patients without mucosal atrophy were significantly lower than in patients with mucosal atrophy. Antitissue transglutaminase values ≥20 IU/mL were found in only 1 patient without mucosal atrophy. CONCLUSIONS. Our study found a strong correspondence between antitissue transglutaminase levels and stage of mucosal injury; antitissue transglutaminase values >20 IU/mL seemed to be strongly predictive of mucosal atrophy.",
keywords = "Antitissue transglutaminase, Celiac disease, Marsh classification",
author = "Antonella Diamanti and Franco Colistro and Angelica Calce and Rita Devito and Francesca Ferretti and Antonio Minozzi and Alexandra Santoni and Massimo Castro",
year = "2006",
month = "12",
doi = "10.1542/peds.2006-0604",
language = "English",
volume = "118",
journal = "Pediatrics",
issn = "0031-4005",
publisher = "American Academy of Pediatrics",
number = "6",

}

TY - JOUR

T1 - Clinical value of immunoglobulin A antitransglutaminase assay in the diagnosis of celiac disease

AU - Diamanti, Antonella

AU - Colistro, Franco

AU - Calce, Angelica

AU - Devito, Rita

AU - Ferretti, Francesca

AU - Minozzi, Antonio

AU - Santoni, Alexandra

AU - Castro, Massimo

PY - 2006/12

Y1 - 2006/12

N2 - OBJECTIVES. Our goal was to evaluate the possible correspondence between antitissue transglutaminase of immunoglobulin A class levels and stage of mucosal damage in patients affected by celiac disease. In addition, we assessed clinical use of antitissue transglutaminase values to predict biopsy results. METHODS. One thousand eight hundred eighty-six consecutive patients with symptoms suggestive of celiac disease and 305 healthy controls underwent determination of serum levels of immunoglobulin A and antitissue transglutaminase. An intestinal biopsy was performed in subjects with antitissue transglutaminase levels ≥4 IU/mL and in subjects with negative antitissue transglutaminase levels but with clinical suspicion of celiac disease. Histologic grading of celiac disease was consistent with the Marsh classification. RESULTS. One hundred eighty-six subjects with positive antitissue transglutaminase levels and 91 patients with negative antitissue transglutaminase levels were submitted to biopsy. In all healthy subjects, antitissue transglutaminase results were negative. Histologic evaluations in patients with positive antitissue transglutaminase levels gave the following results: type 0 in 25 patients, type 1 in 3 patients, type 2 in 4 patients, type 3a in 22 patients, type 3b in 74 patients, and type 3c in 58 patients. None of the patients with negative antitissue transglutaminase levels showed histologic findings suggestive of celiac disease. The mean antitissue transglutaminase values in patients without mucosal atrophy were significantly lower than in patients with mucosal atrophy. Antitissue transglutaminase values ≥20 IU/mL were found in only 1 patient without mucosal atrophy. CONCLUSIONS. Our study found a strong correspondence between antitissue transglutaminase levels and stage of mucosal injury; antitissue transglutaminase values >20 IU/mL seemed to be strongly predictive of mucosal atrophy.

AB - OBJECTIVES. Our goal was to evaluate the possible correspondence between antitissue transglutaminase of immunoglobulin A class levels and stage of mucosal damage in patients affected by celiac disease. In addition, we assessed clinical use of antitissue transglutaminase values to predict biopsy results. METHODS. One thousand eight hundred eighty-six consecutive patients with symptoms suggestive of celiac disease and 305 healthy controls underwent determination of serum levels of immunoglobulin A and antitissue transglutaminase. An intestinal biopsy was performed in subjects with antitissue transglutaminase levels ≥4 IU/mL and in subjects with negative antitissue transglutaminase levels but with clinical suspicion of celiac disease. Histologic grading of celiac disease was consistent with the Marsh classification. RESULTS. One hundred eighty-six subjects with positive antitissue transglutaminase levels and 91 patients with negative antitissue transglutaminase levels were submitted to biopsy. In all healthy subjects, antitissue transglutaminase results were negative. Histologic evaluations in patients with positive antitissue transglutaminase levels gave the following results: type 0 in 25 patients, type 1 in 3 patients, type 2 in 4 patients, type 3a in 22 patients, type 3b in 74 patients, and type 3c in 58 patients. None of the patients with negative antitissue transglutaminase levels showed histologic findings suggestive of celiac disease. The mean antitissue transglutaminase values in patients without mucosal atrophy were significantly lower than in patients with mucosal atrophy. Antitissue transglutaminase values ≥20 IU/mL were found in only 1 patient without mucosal atrophy. CONCLUSIONS. Our study found a strong correspondence between antitissue transglutaminase levels and stage of mucosal injury; antitissue transglutaminase values >20 IU/mL seemed to be strongly predictive of mucosal atrophy.

KW - Antitissue transglutaminase

KW - Celiac disease

KW - Marsh classification

UR - http://www.scopus.com/inward/record.url?scp=33947185256&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33947185256&partnerID=8YFLogxK

U2 - 10.1542/peds.2006-0604

DO - 10.1542/peds.2006-0604

M3 - Article

C2 - 17074840

AN - SCOPUS:33947185256

VL - 118

JO - Pediatrics

JF - Pediatrics

SN - 0031-4005

IS - 6

ER -